Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | TYR | P14679 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9725156 | 0.88 | MAPT (0.78) | MAPTALDH1A1SMN1; SMN2GAAKMT2A | |
| SCHEMBL863314 | 0.85 | MAPT (0.74) | MAPTALDH1A1SMN1; SMN2GAAKMT2A | |
| SCHEMBL5451796 | 0.83 | ALDH1A1 (0.70) | MAPTALDH1A1SMN1; SMN2GAAKMT2A | |
| SCHEMBL725810 | 0.82 | ALDH1A1 (0.75) | MAPTALDH1A1SMN1; SMN2GAAKMT2A | |
| SCHEMBL456513 | 0.80 | MAPT (0.67) | MAPTALDH1A1SMN1; SMN2GAAKMT2A | |
| SCHEMBL1379670 | 0.79 | MAPT (0.66) | MAPTALDH1A1SMN1; SMN2GAAKMT2A | |
| SCHEMBL4154606 | 0.79 | MAPT (0.66) | MAPTALDH1A1SMN1; SMN2GAAKMT2A | |
| SCHEMBL11543444 | 0.78 | ALDH1A1 (0.63) | MAPTALDH1A1SMN1; SMN2GAAKMT2A | |
| SCHEMBL11883991 | 0.77 | ALDH1A1 (0.62) | MAPTALDH1A1SMN1; SMN2GAAKMT2A | |
| SCHEMBL14468544 | 0.76 | MAPT (0.61) | MAPTALDH1A1SMN1; SMN2GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115894884-B | Trifunctional organic catalyst and preparation method and application thereof | 浙江大学 | 2024-07-05 | — | — | CN | disclosed |
| US-20230263167-A1 | METHOD OF PREPARING A BISMUTH SULFIDE PARTICLE CONTAINING ANTIBACTERIAL COMPOSITION | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2023-08-24 | — | — | US | disclosed |
| US-11700855-B2 | Method for preventing or reducing growth of a microorganism on a surface | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2023-07-18 | — | — | US | disclosed |
| CN-115894884-A | Trifunctional organic catalyst, and preparation method and application thereof | 浙江大学 | 2023-04-04 | — | — | CN | disclosed |
| US-20210061670-A1 | METHOD FOR PREVENTING OR REDUCING GROWTH OF A MICROORGANISM ON A SURFACE | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2021-03-04 | — | — | US | disclosed |
| US-10934176-B2 | Methods of degrading organic pollutants and preventing or treating microbe using Bi2S3-CdS particles | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2021-03-02 | — | — | US | disclosed |
| US-10875861-B1 | Therapeutic compounds | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200102228-A1 | METHODS OF DEGRADING ORGANIC POLLUTANTS AND PREVENTING OR TREATING MICROBE USING Bi2S3-CdS PARTICLES | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2020-04-02 | — | — | US | disclosed |
| US-10105687-B1 | Heterostructured Bi2S3—ZnS photocatalysts and methods thereof | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2018-10-23 | — | — | US | disclosed |
| US-20160135464-A1 | PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2016-05-19 | — | — | US | disclosed |
| EP-1054886-B1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 2002-09-04 | — | — | EP | disclosed |
| US-6403633-B2 | USEFUL ANTIANGIOGENIC, ANTIARTHRITIC, ANTIINFLAMMATORY, ANTIRESTENOTIC, ANTIINVASIVE, ANTIMETASTIC, ANTIOSTEOPOROTIC, ANTIRETINOPATHIC, CONTRACEPTIVE AND TUMORISTATIC TREATMENT AGENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-06-11 | — | — | US | disclosed |
| US-20020037915-A1 | Compounds and compositons for treating C1s-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-03-28 | — | — | US | disclosed |
| EP-1150979-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-11-07 | — | — | EP | disclosed |
| US-20010031781-A1 | Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors | ILLIG CARL R (US) | 2001-10-18 | — | — | US | disclosed |
| US-6291514-B1 | Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-09-18 | — | — | US | disclosed |
| EP-1054886-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-11-29 | — | — | EP | disclosed |
| WO-2000047578-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | disclosed |
| WO-1999040088-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1999-08-12 | — | — | WO | disclosed |
| US-4008330-A | A P-AMINOPHENYL-THIOUREA | NIPPON KAYAKU KABUSHIKI KAISHA (JA) | 1977-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037915-A1 | Compounds and compositons for treating C1s-mediated diseases and conditions | C1S, C1R, C9 | MAPT 1954/4885ALDH1A1 3467/4885SMN1; SMN2 953/4885 |
| US-20160135464-A1 | PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO | CYP19A1, CYP1A1, AR | MAPT 3938/4885ALDH1A1 588/4885SMN1; SMN2 3848/4885 |
| US-10875861-B1 | Therapeutic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53, RB1 | MAPT 3759/4885ALDH1A1 1847/4885SMN1; SMN2 1567/4885 |
| US-20010031781-A1 | Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors | SERPINE1, PRSS3, PRSS2 | MAPT 3492/4885ALDH1A1 3209/4885SMN1; SMN2 1864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.